GENMAB AS DKK1 (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage currently has a $177.00 price target on the stock. Zacks Investment Research’s target price indicates a potential upside of 11.85% from the company’s current price.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. started coverage on GENMAB AS DKK1 in a report on Tuesday, June 21st. They issued a “neutral” rating on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of GENMAB AS DKK1 (OTCMKTS:GNMSF) remained flat at $158.25 during trading on Tuesday. GENMAB AS DKK1 has a 12 month low of $93.25 and a 12 month high of $183.00. The stock’s 50 day moving average is $172.39 and its 200 day moving average is $158.34. The stock has a market cap of $9.47 billion, a PE ratio of 94.14 and a beta of 0.89.

Get a free copy of the Zacks research report on GENMAB AS DKK1 (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for GENMAB AS DKK1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB AS DKK1 and related companies with's FREE daily email newsletter.